Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HQL-79 is a selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor. It inhibits the synthesis of PGD2 and acts as an anti-allergic agent (Kd: 0.8 μM and IC50: 6 μM). It also shows no obvious effect on COX-1, COX-2, m-PGES, or L-PGDS.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 114.00 | |
5 mg | 5 days | $ 188.00 |
Description | HQL-79 is a selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor. It inhibits the synthesis of PGD2 and acts as an anti-allergic agent (Kd: 0.8 μM and IC50: 6 μM). It also shows no obvious effect on COX-1, COX-2, m-PGES, or L-PGDS. |
Targets&IC50 | HPGDS:(kd)0.8 μM, HPGDS:6 μM |
In vitro | HQL-79 is a competitive inhibitor against substrate PGH2. HQL-79 is also a non-competitive one against GSH[1]. |
Molecular Weight | 377.48 |
Formula | C22H27N5O |
CAS No. | 162641-16-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
HQL-79 162641-16-9 Others HQL 79 HQL79 inhibitor inhibit